Celgene-partnered Antengene preps new China deals as $21M round lands
Just a few months after inking a deal to develop one of Celgene’s experimental cancer drugs for the Chinese market, Antengene has unveiled a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
